JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Michael David Smith net worth and biography

Michael Smith Biography and Net Worth

VP of KalVista Pharmaceuticals

Michael joined KalVista in February 2016 as Vice President of Clinical Development before being promoted to Senior Vice President of Development. Michael has nearly 20 years of development experience in the pharmaceutical industry. Recent experience includes senior management positions with Global Scientific Affairs, Early Development in the United States and Europe as well as Clinical Development and Regulatory Affairs at a US-based specialty pharma.

Michael received a PharmD from the University of Utah and a BS in Neuroscience from Brigham Young University. He maintains an appointment as Adjunct Assistant Professor, College of Pharmacy, University of Utah.

What is Michael David Smith's net worth?: The estimated net worth of Michael David Smith is at least $101,642.10 as of April 28th, 2021. Dr. Smith owns 10,014 shares of KalVista Pharmaceuticals stock worth more than $101,642 as of November 23rd. This net worth approximation does not reflect any other assets that Dr. Smith may own. Learn More about Michael David Smith's net worth.
How old is Michael David Smith?: Dr. Smith is currently 44 years old. There are 6 older executives and no younger executives at KalVista Pharmaceuticals. The oldest executive at KalVista Pharmaceuticals is Dr. Christopher M. Yea Ph.D., Chief Development Officer, who is 60 years old. Learn More on Michael David Smith's age.
How do I contact Michael David Smith?: The corporate mailing address for Dr. Smith and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Michael David Smith's contact information.
Has Michael David Smith been buying or selling shares of KalVista Pharmaceuticals?: Michael David Smith has not been actively trading shares of KalVista Pharmaceuticals in the last ninety days. Most recently, Michael David Smith sold 10,014 shares of the business's stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $25.76, for a transaction totalling $257,960.64. Following the completion of the sale, the vice president now directly owns 10,014 shares of the company's stock, valued at $257,960.64. Learn More on Michael David Smith's trading history.
Who are KalVista Pharmaceuticals' active insiders?: KalVista Pharmaceuticals' insider roster includes Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Michael Smith (VP), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.
Are insiders buying or selling shares of KalVista Pharmaceuticals?: During the last year, KalVista Pharmaceuticals insiders bought shares 13 times. They purchased a total of 448,522 shares worth more than $5,806,280.30. During the last year, insiders at the specialty pharmaceutical company sold shares 15 times. They sold a total of 236,671 shares worth more than $2,970,743.88. The most recent insider tranaction occured on November, 18th when CEO Benjamin L Palleiko sold 14,400 shares worth more than $133,344.00. Insiders at KalVista Pharmaceuticals own 10.5% of the company. Learn More about insider trades at KalVista Pharmaceuticals.
Information on this page was last updated on 11/18/2024.

Michael David Smith Insider Trading History at KalVista Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/28/2021	Sell	10,014	$25.76	$257,960.64	10,014

Michael David Smith Buying and Selling Activity at KalVista Pharmaceuticals

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $10.15

$9.32

$10.22

50 Day Range

MA: $11.04

$8.96

$12.50

2 Week Range

Now: $10.15

$7.39

$16.88

Volume

404,912 shs

Average Volume

483,637 shs

Market Capitalization

$438.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad